Viatris announces agreements on remaining planned divestitures; upon closing would achieve its original total target of a multiple above 12x on 2022 estimated adjusted ebitda

Total gross proceeds from all divestitures, including the 2022 divestiture of the company's biosimilars business, and the estimated retained value are in line with the company's previously communicated range strategic decision made to retain rights and opportunities for viagra®, dymista® and select over-the-counter (otc) products in certain markets representing approximately $1.6b in estimated retained value total transactions value represents up to $6.94b of total gross proceeds which represents an accretive multiple of 12.4x [1] offer for substantially all of otc business reflects gross consideration of up to approximately $2.17b, representing an estimated accretive multiple of 12.8x; definitive agreements for active pharmaceutical ingredients (api) and women's healthcare reflect gross proceeds of up to approximately $1.2b, representing an estimated accretive multiple of 9.9x combined divestitures would result in up to 12 facilities and more than 6,000 employees representing approximately 15 percent of the company's global workforce being conveyed, substantially simplifying the organization today's announced divestitures expected to close by the end of the first half of 2024, subject to regulatory approvals, consultations and other closing conditions completion of divestitures will bring successful conclusion to all phase 1 efforts and commitments, including prioritizing use of net proceeds for debt paydown to reach gross leverage target [1] of 3.0x in the first half of 2024 pittsburgh , oct. 1, 2023 /prnewswire/ -- viatris inc. (nasdaq: vtrs), a global healthcare company, today announced it has received an offer for the divestiture of substantially all of its over-the-counter (otc) business, and has entered into definitive agreements to divest its women's healthcare business, its active pharmaceutical ingredients (api) business in india and commercialization rights in certain non-core markets that were acquired as part of the upjohn transaction. viatris ceo scott a.
VTRS Ratings Summary
VTRS Quant Ranking